HOW WE OPERATECreating value together

Business models

Milestone based reward

Clearly defined projects are preferably carried out in a milestone-based, fee-for-service model in which all results and any newly generated IP are 100% owned by the client. A clear structure of project work packages and activities is presented in a detailed proposal together with the compensation scheme. An upfront payment and basic fixed fees are paid to cover the direct costs of the R&D work done in each time period. When the pre-defined milestones are reached an achievement fee is paid to fully cover development costs and inventive insight contributed by Enzymicals. There are options to set-up advanced FTE-arrangements for ensuring long-term predictable access to consistent project team.

R&D Partnerships or joint ventures

For certain projects, which are aligned with our strategic orientation, Enzymicals is interested to evaluate to contribute in the technology development reducing the charges compared to a similar fee-for-service project. Through such engagement, Enzymicals becomes a long-term partner with commitment to development and co-participation in the new business IP which was jointly enabled and protected by all partners. Furthermore, Enzymicals is open to assess proprietary early-stage R&D programs with partners from academic and business sectors potentially resulting in licensing agreements or establishing spin-off / joint-venture companies with market-access partners. Such research collaborations work best where the other party is an end-user but does not have the respective in-house capabilities.

Research collaboration

Enzymicals is aiming for strong connections with academic researchers and complementary SMEs in diverse fields of biotechnology and process chemistry. We will engage with other entities with respect to applying for grants towards novel commercial application development and we support research consortia with unique experience in increasing the technology readiness level of new concepts towards technical maturity. Our facility with equipment usable for kg-production of enzymes and/or chemicals is uniquely suited for technology demonstration and piloting. All this makes us a respectable partner for project proposals, related to biotechnology and process chemistry.

Quality and Technologies

We believe that quality and compliance of facilities and products are one of the key mechanisms in providing services and products that are competitive, innovative and exceed customer expectations. Our Quality System covers services and business functions. Our risk analysis technique and procedures cover all production processes, from the start-up of a project to the production and distribution of materials. Our teams are dedicated to continuous improvement, to meet customer expectations and maintain customer confidence.

If new manufacturing processes were the foundation of the original industrial revolution, ‘biomanufacturing’ will be the bioeconomy’s equivalent. We use the concept of in-vitro biosynthesis to produce diverse consumer products.

Enzymes can be much more selective than other catalysts, meaning they can produce more of the desired product and less undesired by-products. In early phase evaluations, we analyze if enzyme-based catalysis has a clear advantage over its alternatives. In addition to constant demands for unbeatable stereoselectivity, this is often the case in dealing with complex molecules or late-stage functionalizations with a strong demand for regioselectivity. In particular, non-productive synthesis steps which only serve to protect functional groups or to activate non-reactive groups can often be bypassed. This shortens synthetic routes and generate fewer by-products, which enables more efficient and resource-saving manufacturing processes.

A key aspect of nature’s synthetic strategy are cascade sequences of biotransformations. We use and apply this to enable super-efficient multi-step reactions by a variety of biocatalytic one-pot systems to build complex molecules from simple starting materials. In combination with innovative membrane reactor techniques and in-situ crystallization based downstream methods, our continuous processes lead to increased resource & energy efficiency with decreased investment & operating costs and a currently urgently needed decreased environmental footprint.

Public track record

50 plus case studies display our achievements – view all:

You can also click on the segments you are interested in.

Enzymicals was supported by numerous EU (FP7, H2020) and domestic (DBU, FNR, BMBF) research grants.

DBU Alliance ChemBioTec: Sustainable biocatalytic oxidation processes. 2011 – 2014

EU FP7: NewProt An interactive protein engineering portal. 2011 – 2015

Biocatalysis 2021: New developments for industrial white biotechnology. 2012 – 2015

SME Innovation program: Production of fine chemicals with recombinant porcine liver esterases. 2012 – 2015

DBU Integrated Biotechnology: Biocatalytic synthesis of functionalized chiral amines by transaminases. 2012 – 2015

SME Innovation program: Sustainable processes for the production of chemically beta-substituted alcohols by novel halohydrin dehalogenases. 2013 – 2015

European Fund for Regional Development: New Bacillus expression and secretion systems for the production of industrial enzymes. 2013 – 2015

Strategic Alliance ZeroCarbFP: Functional biomass from carbon-rich waste streams. 2013 – 2016

EuroTransBio: Bio-based detergents for domestic and industrial washing applications. 2014 – 2017

SME Innovation program: Sustainable synthesis of chiral α-hydroxyketones by coupled enzymatic and chemical catalysis. 2014 – 2017

MSCA-ITN-EID: Sustainable and scalable biocatalytic cascade reactions. 2015 – 2018

EU Horizon2020: Sustainable industrial processes based on a C-C bond-forming enzyme platform. 2015 – 2019

EU Horizon2020: Adding value to camelina and crambe oil. 2015 – 2019

Agency for Renewable Resources: Biocatalytic synthesis of acrylonitrile from renewable resources. 2017 – 2019

EU Horizon2020: Upcycling of PE and PET wastes to generate biodegradable bioplastics for food and drink packaging. 2019 – ongoing

EU Horizon2020: Membranes And Catalysts Beyond Economic and Technological Hurdles. 2019 – ongoing

BMBF Bioeconomy at marine sites: Enzymatic synthesis of marine sugars. 2019 – ongoing

Innovation alliance Plant³: Regional use of macroalgae from the Baltic Sea coast as a renewable resource for a bio-based economy. 2019 – ongoing

SME Innovation program: Biosynthesis of baclofen and related compounds. 2019 – ongoing

SME Innovation program: In-situ crystallization concepts for transaminase reactions. 2019 – ongoing

Memberships

Network of the health industry for Mecklenburg-Western Pomerania

BIO Germany, as the branch association of the biotechnology industry, has set itself the goal of supporting and promoting the development of an innovative branch of industry based on modern biosciences.

Network for fine chemicals in central Germany with representatives from 30 companies and 4 universities. New products and technologies with focus on pharmaceutically relevant intermediates and active ingredients are developed and put into production.

CLIB is an international open innovation cluster of large companies, small and medium-sized enterprises (SMEs), start-ups, academic institutes and universities as well as other actors who are active in biotechnology and the circular and bioeconomy as a whole.

The Plant³ alliance is about to make a substantial contribution to a knowledge- and innovation-based structural change in the north-eastern Mecklenburg-Western Pomerania region. As a bioeconomy region, Plant³ is an alliance with over 70 partners from business, science and society.

IHK acts as a service provider for the economy and acts as a representative of the interests of its members. In doing so, she represents the interests of commercial enterprises vis-à-vis the municipalities, the governments of the federal states and the regional government agencies.

SAP Ariba is the cloud-based marketplace for business-to-business transactions. In the Ariba network, buyers and suppliers can meet virtually and do business.

The Science Exchange Marketplace allows you to source, order, and pay for scientific services from 3,500+ trusted service providers – with only one contract.

Scientist.com is a network of public and private e-commerce marketplaces that connect buyers and sellers of scientific research services.